Acesso Biologics

What Acesso Biologics does

Acesso Biologics is a privately held, for-profit company founded in 2022 and headquartered in Las Vegas, Nevada, with a workforce reported in the 11–50 employee range. Per its firmographic description, the company develops regenerative allograft products, specifically amniotic wound grafts and bone graft substitutes, placing it in the human-tissue biologics segment. The firm operates a website at acessobio.com, but no further technical detail on processing methods, donor-tissue sourcing, FDA registration status, product SKUs, or pricing has been disclosed in the available sources.

Commercially, the most substantive verifiable activity in the source material is a $11 million, five-season sponsorship agreement with UNLV Athletics, under which Acesso Biologics became the first official multi-sport jersey patch partner in NCAA athletics. The deal places the company logo on UNLV football, basketball, and baseball uniforms and includes in-game features and community initiatives, with Learfield acting as the multimedia rights partner facilitating the arrangement. This commitment was framed around anticipated NCAA regulation changes that may expand collegiate sponsorship opportunities.

The source data does not disclose revenue, funding history, management team, ownership structure, certifications, patents, customer logos outside of UNLV, or pricing mechanics. As a result, the operating model — whether Acesso Biologics is presently generating commercial revenue from allograft sales, relying on sponsorship as a brand-building investment, or operating in a pre-commercial phase — cannot be determined from the available evidence.

Name

Acesso Biologics

Website

https://acessobio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Acesso Biologics is a Las Vegas-based private company founded in 2022 that develops regenerative allograft products, including amniotic wound grafts and bone graft substitutes, while also investing in NCAA athletics sponsorship as part of its commercial positioning.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Regenerative allografts
• Amniotic wound grafts
• Bone graft substitutes
• Biologic medical products
• Tissue regeneration

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Core offering

Acesso Biologics develops and supplies regenerative allograft products, including amniotic wound grafts and bone graft substitutes. The products are biologic tissue-based medical offerings intended for clinical use in wound care and bone regeneration procedures.

Product overview

No product or service information is available in the provided source data. The company name "Acesso Biologics" appears in news articles related to a sports sponsorship partnership with UNLV athletics, but no specific product offerings, platforms, or services are described in the accessible sources.

Differentiator

Problem solved

Functional benefit

Products and services

• Amniotic Wound Grafts

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered flagship and core.

• UNLV AthleticsflagshipGTM or Marketing Partner · 8 December 2025Acesso Biologics has become the first official multi-sport jersey patch partner in NCAA athletics. The partnership places the Acesso Biologics logo on UNLV football, basketball, and baseball uniforms for five seasons. The deal also includes sponsorship of in-game features and community initiatives, emphasizing innovation and community engagement ahead of potential NCAA regulation changes.
• LearfieldcoreGTM or Marketing Partner · 8 December 2025Learfield, alongside UNLV Athletics, announced the partnership with Acesso Biologics as the first official jersey patch partner. Learfield acts as the athletic department's multimedia rights partner facilitating the sponsorship arrangement.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• MiMedx Group: MiMedx is a direct peer as a publicly traded developer of amniotic membrane-based wound and surgical recovery products (e.g., EpiFix, AmnioFix), directly competing with Acesso Biologics' amniotic wound graft business and sharing the same regenerative biologics category.
• Organogenesis Holdings: Organogenesis is a direct peer in advanced wound care biologics (Apligraf, Dermagraft, PuraPly), competing head-to-head with Acesso Biologics in the regenerative wound-healing space served by hospitals, wound care centers, and ambulatory clinics.
• MTF Biologics: MTF Biologics is a direct peer as a tissue bank producing allograft wound matrices (e.g., AmnioBand, AlloPatch) and bone graft substitutes, with overlapping product categories, clinical indications, and customer channels to Acesso Biologics.
• AlloSource: AlloSource is a non-profit tissue processor that produces allograft skin substitutes and bone graft substitutes for regenerative use, directly comparable to Acesso Biologics on allograft product type, sourcing model, and clinical application areas.
• LifeNet Health: LifeNet Health is a direct peer in allograft tissue processing and distribution, including wound-care matrices and bone graft substitutes, serving the same hospital and surgeon customer base as Acesso Biologics' dual product platform.

Emerging players

• Surgenex: Surgenex is an emerging player focused on amniotic tissue-based products (e.g., SurForce, SurGraft) for wound healing and soft-tissue applications, comparable as a smaller, single-category competitor to Acesso Biologics' amniotic wound graft line.

Broad incumbents

• Stryker: Stryker is a broad incumbent with significant orthobiologics and bone graft substitute offerings (e.g., through its Wright Medical and Spine division acquisitions), competing in the same orthopedic and spine surgical customer accounts targeted by Acesso Biologics.
• Integra LifeSciences: Integra LifeSciences is a broad incumbent with overlapping portfolios in both wound care (skin substitutes such as Integra Dermal Regeneration Template) and orthobiologics/bone graft substitutes, making it a larger, multi-product competitor across both of Acesso Biologics' target segments.
• Arthrex: Arthrex is a broad incumbent in orthobiologics and sports-medicine surgical products, including bone graft substitutes used in orthopedic procedures — directly overlapping with Acesso Biologics' bone graft substitute business in the orthopedic/sports-medicine channel.
• Smith+Nephew: Smith+Nephew is a broad incumbent in advanced wound management (e.g., PICO, ALLEVYN, skin substitute partnerships) competing in the same wound-care biologics segment where Acesso Biologics' amniotic grafts are positioned.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/AcessoBiologics
• Facebookfacebook.com/acessobioloics
• LinkedInlinkedin.com/company/acesso-biologics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acesso Biologics